Route through Chinese medicine DSM China Gonglue mutation.docVIP

Route through Chinese medicine DSM China Gonglue mutation.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Route through Chinese medicine DSM China Gonglue mutation

 PAGE \* MERGEFORMAT 7 Route through Chinese medicine DSM China Gonglue mutation Recently, the Dutch giant DSM group of antibiotics explicitly rely on 1.3 billion shares of China Pharmaceutical Group and its listed companies, and in the field of vitamins and anti-infective form a joint venture. Concerning this multinational giant, the leading pharmaceutical companies with the domestic industrial integration between the achievements of the year will be the biggest pharmaceutical industry mergers and acquisitions. Has been cautious in the Chinese market ahead of the pharmaceutical business strategy, DSM mutation is taking place. DSM Pharmaceutical production and technology transfer to China of double, and the Chinese drug’s manufacturing cost advantage and sales network, will enable DSM and Chinese medicine to vitamins and antibiotics to seek the two areas of greater right to speak. Industry analysis, the two sides of the joint will give a strong impact on China’s industrial pattern of antibiotics, and its domestic Cheong Hang Road, the ‘Indian goods’ sales have an impact. DSM 1.3 billion gamble on Chinese medicine At present, the product aging, drug prices drop and the rise of strong competitors, and many other factors are the Sun, it was pushed into the unlimited North China Pharmaceutical Market frustrated torment period. According to statistics of China Galaxy Securities analyst Yan-Ming Liu, North China Pharmaceutical in 1998 and 1999 account for the pharmaceutical industry’s first one-float market capitalization has now slipped to 25 outside. Recently, North China Pharmaceutical notice issued full-year results are expected for the full year 2005 results for a loss. However, vitamins and antibiotics, industrial magnates DSM’s eyes, also has two core business of the North China Pharmaceutical is still a potential to be tapped for ‘meat and potatoes’, DSM is planning a bigger vitamins and antibiotics, industrial clusters . DSM Chairman and CEO, Ai Fu-ti

文档评论(0)

hhuiws1482 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:5024214302000003

1亿VIP精品文档

相关文档